

Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

NCT07234838

Status RECRUITING
Sponsor Jonathan Krygier
Enrollment 600 participants

Key Eligibility Criteria

Inclusion (4)

- Age e 18 years
- Moderate to severe psoriasis (BSA \geq 10% or PASI \geq 10), prior to initiation of the current therapy at the time of inclusion
- Planned dermatological follow-up for approximately 24 months, with no additional visits required by the study
- Signed informed consent

Exclusion (1)

- Severe immunosuppression not related to psoriasis or its therapy (concomitant treatment with major immunosuppressants, uncontrolled HIV infection, or other conditions inducing significant immunosuppression)

Locations (3 total)

CHU Saint-Pierre, Brussels, Brussels Capital, Belgium
CHU Brugmann, Brussels, Brussels Capital, Belgium
Hôpital Erasme, Brussels, Brussels Capital, Belgium